c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL)
c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL)
c-Abl 导向的苯丁酸氮芥分子重组为慢性淋巴细胞白血病 (CLL) 患者提供新的治疗选择
批准号：
211089
负责人：
Panasci Lawrence C
金额：
$20.44万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-09-01 至 2013-09-01
关键词：
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The treatment of chronic lymphocytic leukemia (CLL) has improved with combinations of different drugs and antibodies, but cure of CLL remains elusive. One of the standard drugs used in the treatment of CLL is a nitrogen mustard analogue (cyclophosphamid
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
